Since the FDA approved the first statin in 1987, the benefits of statins have gradually become better known. Over the past decade, the completion of several world-renowned international trials on the prevention and treatment of coronary heart disease has confirmed that statins can reduce the morbidity and mortality of coronary heart disease and can slow down or even reduce the development of established atherosclerotic plaques, thus breaking the traditional notion that coronary heart disease is irreversible. This has led to the rise of a global lipid revolution. In recent years, the pleiotropic nature of statins, i.e., “benefits beyond lipid lowering. Statins may delay the decline in lung function in smokers and former smokers, and this effect of statins is independent of the type of underlying lung disease in the study population. Statin use was associated with improved survival in patients with acute exacerbations of COPD, and the combination of inhaled glucocorticoids (ICS) was associated with improved prognosis. Most studies support the beneficial effects of statins in patients with infections and sepsis. Statins can improve endothelial cell function and arterial stiffness, reduce RA activity, and decrease the number of swollen joints in patients with rheumatoid arthritis (RA). Therefore, statins may be used selectively in patients with active RA who have a long history of disease and increased cardiovascular risk. Statin use in patients with coronary artery disease (CAD), diabetes mellitus, or non-CAD patients at high cardiovascular risk may reduce their risk of stroke. The risk of atrial fibrillation was significantly lower in those on statins [ratio (OR)=0.39]. The most significant effect of statin was on secondary prevention of AF (OR=0.33), followed by prevention of new-onset and post-surgical AF (OR=0.60). All-cause mortality (36% versus 16%) and the incidence of sudden death (5% versus 22%) were significantly lower in statin-treated patients with heart failure. Survival without sudden death was 2.3 times higher in statin-treated patients than in controls. After the UCSD statin trial, it was suggested that these drugs may also have antihypertensive effects, which in turn may exert beneficial effects on the cardiovascular system. In this study, statin treatment resulted in a 2-3 mmHg decrease in blood pressure. However, statins are not “magic drugs” and all drugs have varying degrees of side effects. More than 10 years of evidence-based history has shown that not only the efficacy of statin is supported by abundant evidence, but also the understanding of statin adverse effects has undergone a gradual change, and the safety of statin has been fully affirmed so far. As the evidence-based basis for statin lipid lowering continues to accumulate, the clinical application of statin continues to develop in breadth and depth, and more and more patients receive statin therapy, so the absolute number of adverse reactions will also rise. Therefore, a correct understanding of statin safety is necessary to implement clinical guidelines and promote clinical lipid-lowering practice.